This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
PROs were included as exploratory endpoints in this open-label study; analyses were prespecified and adjustments for multiplicity were not made. No efficacy conclusions can be made from these data.2
PROs were included as exploratory endpoints in this open-label study; analyses were prespecified and adjustments for multiplicity were not made. No efficacy conclusions can be made from these data.2
Legal Category: S1A
Further information is available upon request
Superior to chemotherapy in delaying disease progression4
AEs were manageable with a low discontinuation rate4
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023